Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Khan, Nawazish
NCT06568692: A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer	Recruiting	2	90	US	PCS6422 and capecitabine, Capecitabine	Processa Pharmaceuticals	Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer	09/26	10/26
NCT06764940: A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients with Brain Metastases	Recruiting	2	120	US	Utidelone, Utidelone in combination with capecitabine	Biostar Pharma, Inc.	HER2-negative Breast Cancer Patients with Brain Metastases	01/27	07/27
SRF114-101, NCT05635643: Study of CHS-114 in Participants With Advanced Solid Tumors Jan 2024 - Jun 2024 : Results from SRF114-101 trial for advanced solid tumors	Recruiting	1	87	US	CHS-114, toripalimab, Loqtorzi	Coherus Biosciences, Inc.	Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma	02/26	02/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Khan, Nawazish
NCT06568692: A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer	Recruiting	2	90	US	PCS6422 and capecitabine, Capecitabine	Processa Pharmaceuticals	Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer	09/26	10/26
NCT06764940: A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients with Brain Metastases	Recruiting	2	120	US	Utidelone, Utidelone in combination with capecitabine	Biostar Pharma, Inc.	HER2-negative Breast Cancer Patients with Brain Metastases	01/27	07/27
SRF114-101, NCT05635643: Study of CHS-114 in Participants With Advanced Solid Tumors Jan 2024 - Jun 2024 : Results from SRF114-101 trial for advanced solid tumors	Recruiting	1	87	US	CHS-114, toripalimab, Loqtorzi	Coherus Biosciences, Inc.	Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma	02/26	02/26